Dr. Younes on R-CHOP in Combination with Ibrutinib in DLBCL

Video

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses a phase III study of ibrutinib in combination R-CHOP in patients with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma.

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses a randomized, double-blind, placebo-controlled phase III study of ibrutinib in combination R-CHOP in patients with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL).

Younes says this trial is important because this is a subpopulation of patients that have an unmet medical need. Comparatively, these patients do not do as well as other patients when they are treated with standard R-CHOP chemotherapy. Their progression-free and overall survival is suboptimal compared to patients without the nongerminal center B-cell subtype, Younes says.

Because of this, there is a lot of interest in developing new treatments for this population. This trial, which is currently in progress, adds ibrutinib to R-CHOP compared to R-CHOP plus placebo. The experience of single-agent ibrutinib was the rational behind this trial. In this study, patients with relapsed diffused large lymphomas experienced an increase in response rate.

<<<

View more from the 2014 ASCO Annual Meeting

Related Videos
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center